How Yervoy Dosage Is Calculated by Weight
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, uses weight-based dosing in most approved regimens. The standard adult dose is 3 mg/kg intravenously every 3 weeks for up to 4 doses, often combined with nivolumab (Opdivo). Dosage is calculated as total body weight in kilograms multiplied by 3 mg, then administered over 90 minutes.[1][2]
For example:
- 60 kg patient: 180 mg per infusion
- 80 kg patient: 240 mg per infusion
- 100 kg patient: 300 mg per infusion
Higher weight means higher absolute dose to maintain consistent drug exposure (area under the curve).[3]
Fixed Dosing in Combination Regimens
In some nivolumab + Yervoy combinations (e.g., for melanoma, renal cell carcinoma, or MSI-H/dMMR cancers), Yervoy shifts to a fixed 1 mg/kg every 6 weeks for up to 4 doses, still weight-based but lower intensity. Beyond that, it's weight-adjusted only if needed clinically.[1][4]
No fixed-dose options exist for Yervoy monotherapy.
Adjustments for High or Low Weight
- Obesity (BMI >30 kg/m²): Use actual body weight unless toxicity risk is high; no cap specified, but some trials capped at 100-120 kg to avoid overdose. Monitor closely for immune-related adverse events (irAEs).[3][5]
- Underweight patients: No minimum weight; dose by actual body weight, but adjust for frailty or organ function.
- Pediatric use (12+ years, >40 kg): Same 3 mg/kg or 1 mg/kg mg/kg as adults; not studied below 40 kg.[1]
Why Weight Matters: Pharmacokinetics and Safety
Yervoy's clearance correlates with body weight, so fixed dosing risks underexposure in heavier patients or toxicity in lighter ones. Weight-based dosing targets steady-state exposure, reducing variability in efficacy and side effects like colitis or hepatitis.[3][6] Simulations show 20-30% exposure differences without adjustment.[5]
Common Patient Concerns with Weight Changes
Patients gaining/losing >10% body weight between cycles recalculate dosage using current weight. Pregnancy or rapid obesity may prompt physician review for safety.[2][7] Overweight patients report higher irAE rates, possibly from larger doses.[6]
[1]: Yervoy Prescribing Information (Bristol Myers Squibb)
[2]: FDA Label for Ipilimumab
[3]: Clinical Pharmacology Review - Ipilimumab
[4]: NCCN Guidelines - Melanoma (Version 2.2024)
[5]: ASCO Post: Weight-Based Dosing in Immunotherapy
[6]: J Clin Oncol: Ipilimumab PK in Obese Patients (2018)
[7]: DrugPatentWatch.com - Yervoy Patents and Exclusivity